About 50% of patients with severe chronic spontaneous urticaria (CSU) show signs of activation of the coagulation/fibrinolysis system, but the clinical significance of this phenomenon is unclear.
was first described about 12 years ago (1) . Such phenomenon, which is clearly associated with disease severity (2) , seems to occur via the activation of the extrinsic pathway of the coagulation cascade (1). This finding was confirmed over time by several research groups (3) (4) (5) (6) , one of whom also showed that the activation of the extrinsic pathway of the coagulation might in turn activate the intrinsic pathway also, eventually producing a hyper-coagulable pattern (7) . The activation of the coagulation/fibrinolysis system is possibly a consequence of the hyper-expression of tissue factor by activated eosinophils (8) , although also endothelial cells seem able to play a role in this sense (9) . The activation of the coagulation system in CSU occurs irrespectively of the presence or absence of autoreactivity (5, 10) , and has been shown to be negatively associated with patients' response to second-generation antihistamines (11) . Although increased plasma levels of D-dimer are not predictive of CSU patients' response to the humanized anti-IgE mAb, Omalizumab (12) , it nonetheless parallels the clinical response to this drug (13) . Patients with severe CSU show a detectable activation of the coagulation cascade in about 50% of cases (12) . What differentiates patients with severe CSU showing and not showing the activation of the coagulation/fibrinolysis system has not been established so far. The present study compared the clinical features in these two subsets of patients with CSU. with severe CSU (UAS-7 > 30) unresponsive to antihistamine treatment. The study group was divided based on baseline D-dimer plasma levels, which were measured by ELISA and expressed as ng/ml; values exceeding 500 ng/ml were considered elevated. The following parameters were investigated: age, sex, disease duration (in months), disease activity (expressed as UAS-7 value), CRP, thyroid autoimmunity (defined as the presence of circulating IgG autoantibodies specific for thyroperoxidase and/or thyroglobulin), total IgE, and atopic status (defined as a positive history of respiratory and/or food allergy confirmed by positive SPT with commercial allergen extracts). Patients gave an informed written consent to the use of their data in anonymous form. Since the study was retrospective and based on routine diagnostic tests, a formal approval by an external ethical committee was not required.
Statistics
Means and proportions were compared by two-tailed Student's t-test and by chi-square test with Yates' correction, respectively. Probability values less than 5% were considered statistically significant. unquestionably associated with a severe disease (2) , not all patients with severe CSU do show elevated Ddimer plasma levels. This study, which was focused specifically on subjects with severe CSU (UAS7 > 30) refractory to antihistamine treatment, confirmed that elevated D-dimer plasma levels are found only in 50%.
The reasons for this are not yet clear. Patients showing signs of activation of the coagulation/fibrinolysis system were frequently older females with a longer disease duration showing a systemic inflammatory milieu, as suggested by the higher frequency of elevated CRP, a non-specific marker of inflammation. In a recent study, about one third of CSU patients showed elevated CRP levels, often in association with a positive autologous serum skin test, a marker of autoreactivity (14) . The association between coagulation/fibrinolysis and inflammation markers has been observed about 9 years ago (15) and confirmed more recently (16, 17) .
Altogether, these findings seem to suggest the existence of a phenotype of CSU characterized by more intense, clinically detectable inflammatory events, as also shown by studies that investigated different inflammation markers (18, 19) , that would involve the coagulation system. On the other hand, this study suggests that severe CSU may occur in the absence of any clinically detectable inflammation. Whether this reflects the existence of different endotypes in patients showing and not showing the activation of the coagulation cascade has still to be established.
The inflammatory milieu involving the activation of coagulation/fibrinolysis system does not seem to interfere with the clinical response to omalizumab (12) , suggesting that the activated coagulation cascade probably acts as a secondary amplification mechanism rather than the leading actor in this disease. The inflammatory milieu suddenly normalizes in CSU patients responding to omalizumab (13) , suggesting that the interaction between autoreactive IgE (20) and their ligands is a likely starting point of the inflammation process, and that their neutralization by anti-IgE leads to the "shutdown" of the whole mechanism. Patients showing elevated D-dimer M a n u s c r i p t a c c e p t e d f o r p u b b l i c a t i o n levels are often unresponsive to antihistamines (11, 16) , but this seems the case also in patients lacking signs of systemic inflammation, as shown by the present study. 
